« Return to News | Awards & Advancement

BioStat’s rED Cap software receives trademark status

Thursday, February 2, 2012 09:02 AM

BioStat International’s rED Cap, proprietary, web-based clinical trial data management software, has received trademark status. This distinction follows the October 2011 rollout of rED Cap during the BioFlorida Annual Conference.

Thanks to its navigation and usage-based, zero-licensing pricing model, rED Cap has received strong accolades in its first few months of release.

For multi-site clinical research trials, pharmaceutical research, development and marketing and medical observational studies, rED Cap provides a comprehensive Web-based data management solution to collect and store data, all in a secure environment (rED Cap meets compliance requirements for both HIPAA and CFR21 Part 11).

To support quality research, rED Cap also features a customizable electronic case report form, flexible workflow, dynamic reporting and data status and powerful data validation capability. BSI data management CRO service—offered with each rED Cap study—can provide assistance to a research team in efficient project management and experienced data analysis for meeting study objectives.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.